We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

MAPKAPK2 (MK2)

MK2 inhibitors act on MAPKAPK2, a protein kinase switched on by p38 MAP kinase in stress and inflammation. Mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MAPKAPK2, MK2) was described in 1992 as a kinase activated by MAPK phosphorylation. Its substrates include heat shock protein 27 (HSP27) and proteins that control the stability of cytokine messenger RNAs. Mice lacking MK2 resist endotoxic shock and make far less tumor necrosis factor alpha (TNF-α) after lipopolysaccharide (LPS) challenge. PF-3644022 and MK2-IN-1 inhibit the kinase directly, and MMI-0100 is a cell-permeant peptide inhibitor. p38α-MK2-IN-1 targets the p38α-MK2 complex, and GLPG0259 is listed for the related kinase MAPKAPK5. Inhibitors of p38 itself, the upstream activator of MK2, are found under p38-MAPK.

1 Item

  • Peraquinsin
    Cat. No.
    A65798
    CAS No.
    35265-50-0

    Peraquinsin

    Peraquinsin is a potent MK2 activator that enhances the activity of mitogen-activated protein kinase-activated protein kinase 2 (MK2). This compound is primarily utilized in research pertaining to vascular disorders and endothelial barrier dysfunction. Additionally, Peraquinsin exhibits antihypertensive properties, making it valuable in studies focused on regulating blood pressure and vascular health.

    In stock View Details
    5 mg
    $100.00
    10 mg
    $170.00
    All 4 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...